Nucleoside Metabolic Inhibitor [EPC]

156110 reported adverse events

Drugs of this class: FLUOROURACIL CAPECITABINE DECITABINE AZACITIDINE CLOFARABINE CYTARABINE TRIFLURIDINE (DAUNORUBICIN AND CYTARABINE) LIPOSOME CEDAZURIDINE AND DECITABINE NELARABINE PENTOSTATIN TRIFLURIDINE AND TIPIRACIL

These side effects are most commonly reported by patients taking drugs of the Nucleoside Metabolic Inhibitor [EPC] class:

# Side effect Count
0 DIARRHOEA 15421
1 DEATH 12385
2 NAUSEA 10439
3 VOMITING 8598
4 FEBRILE NEUTROPENIA 8494
5 NEUTROPENIA 8228
6 DISEASE PROGRESSION 7524
7 FATIGUE 7329
8 PYREXIA 7309
9 THROMBOCYTOPENIA 5680
See all common reactions for Nucleoside Metabolic Inhibitor [EPC]

Drugs of the Nucleoside Metabolic Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY 131 0.8618
1 HUMAN BOCAVIRUS INFECTION 83 0.7094
2 ACUTE MYELOID LEUKAEMIA RECURRENT 397 0.4344
3 MYELODYSPLASTIC SYNDROME TRANSFORMATION 175 0.3631
4 CAECITIS 163 0.3622
5 PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME 5190 0.3569
6 MYCOBACTERIUM CHELONAE INFECTION 147 0.3349
7 DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY 82 0.3228
8 NEUTROPENIC COLITIS 310 0.3116
9 TRANSFORMATION TO ACUTE MYELOID LEUKAEMIA 104 0.3104
See all enriched reactions for Nucleoside Metabolic Inhibitor [EPC]